07.01.2022 13:14:54
|
908 Devices: GSK Selects REBEL Desktop Device As Part Of Its Process Development Efforts
(RTTNews) - 908 Devices (MASS) announced that GlaxoSmithKline (GSK) has purchased an additional REBEL cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams.
REBEL is the first miniature CE-MS-based analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line. 908 Devices noted that there are now 15 customers owning multiple REBEL devices, more than double from a year ago.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu 908 Devices Inc Registered Shsmehr Nachrichten
11.11.24 |
Ausblick: 908 Devices zieht Bilanz zum jüngsten Jahresviertel (finanzen.net) | |
28.10.24 |
Erste Schätzungen: 908 Devices öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Analysen zu 908 Devices Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
908 Devices Inc Registered Shs | 2,51 | -7,72% |
|